| 0.2599 -0.013 (-4.83%) | 12-07 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.58  |
1-year : | 0.79 |
| Resists | First : | 0.49 |
Second : | 0.67 |
| Pivot price | 0.33 |
|||
| Supports | First : | 0.21 |
Second : | 0.17 |
| MAs | MA(5) : | 0.29 |
MA(20) : | 0.34 |
| MA(100) : | 3.04 |
MA(250) : | 4.13 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 8.3 |
D(3) : | 6.4 |
| RSI | RSI(14): 21.9 |
|||
| 52-week | High : | 15.5 | Low : | 0.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KTRA ] has closed below the lower bollinger band by 1.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ KTRA ] is to continue within current trading range. It is unclear right now based on current values. 91.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.33 - 0.33 | 0.33 - 0.34 |
| Low: | 0.21 - 0.21 | 0.21 - 0.21 |
| Close: | 0.26 - 0.26 | 0.26 - 0.26 |
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Tue, 05 Dec 2023
Kintara granted extension by Nasdaq to regain compliance with continued listing rules - Seeking Alpha
Tue, 05 Dec 2023
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued ... - Yahoo Finance
Mon, 13 Nov 2023
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update - Yahoo Finance
Wed, 01 Nov 2023
Why Kintara Therapeutics (KTRA) Shares Are Getting Obliterated - Kintara Therapeutics (NASDAQ:KTRA) - Benzinga
Tue, 31 Oct 2023
Why Kintara Therapeutics Stock Is Down 70% Tuesday - Kintara Therapeutics (NASDAQ:KTRA) - Benzinga
Tue, 31 Oct 2023
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 3.2 (%) |
| Shares Short | 539 (K) |
| Shares Short P.Month | 37 (K) |
| EPS | -7.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -7.24 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -111.6 % |
| Return on Equity (ttm) | -342.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|